Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New BMBF Project: Cell death blocker against neurodegeneration and dementia

14.11.2017

With the VIP+ programme, the Federal Ministry of Education and Research (BMBF) strives to close the gap between basic research and possible translational applications. In November 2017, such a project will also start at the Helmholtz Zentrum München: Scientists here will receive a total of 1.5 million Euros over the course of the next two years for their work against neurodegenerative diseases.

Age-related neurodegenerative diseases are regarded to be one of the most important medical challenges of the coming decades. In Germany alone more than 1.5 million people are living with dementia, two thirds of whom are suffering from Alzheimer’s disease.


Ferroptotic neurons in the murine cortex. Nuclei are stained in blue, ferroptotic cells in green.

Source: Helmholtz Zentrum München

In view of the demographic change, the prevalence of neurodegenerative diseases is continuously increasing and thus represents not only a major health problem but also a growing socio-economic burden. In addition, while a fraction of neurodegenerative diseases is less associated with age, they are still fatal, such as amyotrophic lateral sclerosis (ALS) or Huntington’s disease.

Although different regions of the brain and neurons are usually affected, the early and progressive loss of nerve cells is a common hallmark of these illnesses. The latest results prove that neuronal cell death is largely caused by regulated necrotic cell death mechanisms, including ferroptosis, a novel form of cell death marked by iron-dependent lipid peroxidation*. This important insight allows the development of substances that may prevent the death of neurons.

Liproxstatin as a neuroprotective agent

In extensive preliminary work Helmholtz researchers led by Dr. Marcus Conrad at the Helmholtz Zentrum München screened more than 40,000 new substances for their anti-ferroptotic properties. Thereby, the chemical class of spiroquinoxalines (termed liproxstatins) stood out particularly for its strong cell-protective activity, drug-like property and its proven efficacy in various animal models of degenerative disease. Subsequent lead optimisation studies resulted in the identification of substances that could efficiently cross the blood-brain barrier and are therefore considered as promising neuroprotective agents.

Meanwhile, the Conrad group has also been able to demonstrate the molecular effects of liproxstatins in the context of ferroptosis. With the VIP+ programme they now want to take the next step and validate the efficacy of these potentially neuroprotective agents in pre-clinically relevant models of neurodegenerative disease.

“Up to now, neurodegenerative conditions have been inadequately treated and, if so, mostly symptomatically,” explains Dr. Marcus Conrad, group leader at the Institute for Developmental Genetics (IDG). “Ferroptosis inhibitors could, for the first time, lead to the development of a new and effective therapeutic approach to prevent the progressive loss of nerve cells at an early stage,” adds IDG scientist Dr. Bettina Proneth.

Accordingly, Conrad and his team hope that within the framework of the VIP+ programme a key milestone will be reached that will constitute not only the basis for further pre-clinical development on the road to medical approval and application, but will also spark great interest among pharma industry and venture capitalists for further (pre) clinical development.

Further Information

Background:
The term ferroptosis was coined in 2012. It is derived from the Greek word ptosis, meaning “a fall”, and ferrum, the Latin word for iron, and describes a form of regulated cell death in which iron plays an important role. “The individual mechanisms involved in this type of cell death emerge only slowly, and our team has already delivered some groundbreaking work that is contributing towards a better understanding of ferroptosis,” says Dr. Marcus Conrad, who heads the working group at the IDG.

The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en

Rising life expectancy is causing an increase in age-related, but also sociological and environmental, influences on the genes. The Institute of Developmental Genetics (IDG) examines these changes in genetic material. In the Mouse Genetics group, genetic animal models are developed to investigate various diseases. These models are analyzed in the Disease Modelling research group in order to identify gene functions and cell processes and evaluate the influence of the environment and aging processes. The group focuses on the examination of neurological and psychiatric diseases. http://www.helmholtz-muenchen.de/idg

Contact for the media:
Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - Fax: +49 89 3187 3324 - E-mail: presse@helmholtz-muenchen.de

Scientific Contact at Helmholtz Zentrum München:
Dr. Marcus Conrad, Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Developmental Genetics, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 4608, E-mail: marcus.conrad@helmholtz-muenchen.de

Sonja Opitz | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

Further reports about: BMBF Genetics IDG cell death dementia neurodegenerative diseases

More articles from Life Sciences:

nachricht Complete skin regeneration system of fish unraveled
24.04.2018 | Tokyo Institute of Technology

nachricht Scientists generate an atlas of the human genome using stem cells
24.04.2018 | The Hebrew University of Jerusalem

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Complete skin regeneration system of fish unraveled

24.04.2018 | Life Sciences

Scientists create innovative new 'green' concrete using graphene

24.04.2018 | Materials Sciences

BAM@Hannover Messe: innovative 3D printing method for space flight

24.04.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>